[TuPe1.1C28] HCV co-infection among HIV-1 infected persons in an Argentinean province: Distribution of HCV-Genotype in different risk groups

3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Rio de Janeiro - July 24 - 27, 2005

HCV CO-INFECTION AMONG HIV-1 INFECTED PERSONS IN AN ARGENTINEAN PROVINCE: DISTRIBUTION OF HCV-GENOTYPE IN DIFFERENT RISK GROUPS

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPe1.1C28

Fay F.¹, Campodonico M.¹, Benetti S.¹, Lejona S.¹, Bortolozzi R.², Gambino P.³, Amin M.⁴, Fay O.⁵
¹CIBIC, Rosario, Argentina, ²Hospital Alberdi, Rosario, Argentina, ³Hospital Iturraspe, Santa Fe, Argentina, ⁴Hospital Cullen, Santa Fe, Argentina, ⁵CTSP - Universidad Nacional de Rosario, Rosario, Argentina

OBJECTIVES: Estimate HCV co-infection rate and HCV-Genotype distribution among HIV-1 infected persons in different risk groups from Santa Fe, Argentina.

METHODS: First visit from 250 HIV-1 infected patients attending our center for treatment monitoring from 1997 to 2004 were retrospectively selected according to risk group proportions reported by the province to the National AIDS Program in 2003 : 36% intravenous drug users (IDU), 19% homosexuals (HOM), 7% vertical transmitted (MCT), and 38% heterosexuals (HET). Anti-HCV ELISA (Cobas Core, Roche) and HCV-RNA PCR (detection limit: 100 UI/ml) were performed blindly in plasma samples retrieved from -80°C storage. HCV genotype was defined by PCR-RFLP in positive HCV-RNA samples. A positive result for HCV-RNA or Anti-HCV was considered as a co-infection HCV/HIV.

RESULTS: 120 (48%) out of 250 HIV patients were co-infected with HCV. Among them, 87 (72,5%) were both positive for Anti-HCV and HCV-RNA, 15 (12,5%) were only Anti-HCV(+) while 18 (15%) were HCV-RNA (+), Anti-HCV (-). Co-infection rate per risk group were: IDU 85% (78/92); HOM 17% (9/52); MCT 9.5% (2/21); HET 36% (31/85). HCV replication per risk group were: IDU: 87% (68/78); HOM: 88% (8/9); MCT 50% (1/2); HET 90%(28/31). HCV genotype per risk group were: IDU: 1 - 69% (47/68), 2 - 4% (3/68), 3 - 26%(18/68) ; HOM: 1 - 50% (4/8), 2 - 38% (3/8), 3 - 13%(1/8); MCT: 1 - 100% (1/1); HET: 1 - 86% (24/28), 2 - 4% (1/28), 3 - 11%(3/28).

CONCLUSIONS: Observed global HCV co-infection prevalence among HIV-1 infected people in Santa Fe was 48% (95% CI: [41.7;54.3]). HCV replication was observed in 87.5% (95% CI: [81.6;93.4]) of co-infected patients without significant difference among risk groups (p>0.05). Genotype 1 was prevalent (72% [63.4;80.6]) despite risk group (p>0.05). Anti-HCV(-) with HCV-RNA(+) observed in 15% of co-infected patients emphasizes the importance of using PCR as HCV screening tool in HIV-1 infected patients.

Download PDF of this abstract.

050724
Clinical | TuPe1.1C28 | Fabián Fay
Hepatitis viruses

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.